FDF

Frontiers of Digital Finance by Biz2X Named as Fintech Ecosystem Partner for the Dubai FinTech Summit 2024 on May 8

Retrieved on: 
Wednesday, March 27, 2024
Element, Mastercard, Growth, Entrepreneurship, Qarar, DLA, FDF, Credit bureau, AI, AWS, KSA, Kingdom, Piper, Vision 2030, DLA Piper, Frontiers

DUBAI, United Arab Emirates, March 27, 2024 (GLOBE NEWSWIRE) -- Biz2X and Dubai International Financial Centre ( DIFC ) today announced that Frontiers of Digital Finance (FDF) will be an official event at the 2024 Dubai FinTech Summit.

Key Points: 
  • DUBAI, United Arab Emirates, March 27, 2024 (GLOBE NEWSWIRE) -- Biz2X and Dubai International Financial Centre ( DIFC ) today announced that Frontiers of Digital Finance (FDF) will be an official event at the 2024 Dubai FinTech Summit.
  • FDF Dubai will feature key industry leaders from financial institutions, technology platforms, global consultancies, and government officials in an invite-only event on May 8, 2024.
  • In collaboration with DIFC Innovation Hub, the event will also spotlight Dubai's groundbreaking Vision D33 for transforming finance in the Emirates.
  • We are proud to be hosting these urgent and powerful conversations with the Frontiers of Digital Finance series."

Frontiers of Digital Finance by Biz2X Named as Fintech Ecosystem Partner for the Dubai FinTech Summit 2024 on May 8

Retrieved on: 
Wednesday, March 27, 2024
Element, Mastercard, Growth, Entrepreneurship, Qarar, DLA, FDF, Credit bureau, AI, AWS, KSA, Kingdom, Piper, Vision 2030, DLA Piper, Frontiers

DUBAI, United Arab Emirates, March 27, 2024 (GLOBE NEWSWIRE) -- Biz2X and Dubai International Financial Centre ( DIFC ) today announced that Frontiers of Digital Finance (FDF) will be an official event at the 2024 Dubai FinTech Summit.

Key Points: 
  • DUBAI, United Arab Emirates, March 27, 2024 (GLOBE NEWSWIRE) -- Biz2X and Dubai International Financial Centre ( DIFC ) today announced that Frontiers of Digital Finance (FDF) will be an official event at the 2024 Dubai FinTech Summit.
  • FDF Dubai will feature key industry leaders from financial institutions, technology platforms, global consultancies, and government officials in an invite-only event on May 8, 2024.
  • In collaboration with DIFC Innovation Hub, the event will also spotlight Dubai's groundbreaking Vision D33 for transforming finance in the Emirates.
  • We are proud to be hosting these urgent and powerful conversations with the Frontiers of Digital Finance series."

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

Retrieved on: 
Thursday, March 21, 2024
API, Patient, POS, FDF, Pharmaceutical industry

The new facility and automated production lines will increase production capacity by 20% compared to the current capacity of 200 million packages per year.

Key Points: 
  • The new facility and automated production lines will increase production capacity by 20% compared to the current capacity of 200 million packages per year.
  • Gilbert Ghostine, Chairman Sandoz, said: "Antibiotics are the backbone of modern medicine and Kundl is a testament to the resilience of European manufacturing.
  • This allows us to address growing demand and further strengthens our commitment to our unique European-based antibiotic production network."
  • Richard Saynor, CEO Sandoz, said: "Kundl, as the hub and center of our antibiotic production, is a true lighthouse project when it comes to security of antibiotic supply.

Global Microbiome Manufacturing Markets 2023-2024 & 2035: Industry Trends, Forecasts, Formulation, Primary Packaging Used, Scale of Operation, Company Size, Key Regions and Leading Developers - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Vitamins, Supplements, Neurology, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Alternative Medicine, General Health, Pharmaceutical, Health, Clostridioides difficile infection, Type, Organization, Database, AOBiome, Microbiota, Patient, CNS, CGMP, Research, Fungus, FDF, Bacteria, Virus, Laboratory, Overalls, Infection, DSM-IV codes, API, Safety, Phase, Therapy, USD, LBP

Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome.

Key Points: 
  • Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome.
  • Further, this microbiome manufacturing market analysis highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • Around 43% of the global microbiome contract manufacturing capacity is installed in facilities owned by small contract manufacturing companies.
  • This market report includes an easily searchable excel database of all the microbiome contract manufacturing companies and their manufacturing facility, worldwide.

Pharmaceutical Contract Manufacturing Market Size to Hit USD 140 billion by 2030 Say, Roots Analysis

Retrieved on: 
Monday, January 15, 2024
Warburg Pincus, HUF, Blister, Overalls, Route of administration, API, OneSource, Advent International, Investment, Acquisition, Drug development, Stelis, FDF, Baxter International, Organization, CDMO, CMOS, Egis, Clinical trial, Growth, Fine chemical

LONDON, Jan. 15, 2024 /PRNewswire/ -- The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reach USD 140 billion by 2030. It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period (2022-2030). 

Key Points: 
  • The global pharmaceutical contract manufacturing market faces challenges in the form of high initial investment costs for equipment and facilities.
  • Commercial segment will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 81% by 2030.
  • Based on the type of end users, the pharmaceutical contract manufacturing market is segmented into small, mid-sized, and large pharmaceutical companies.
  • Asia-Pacific will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 37% of the market share by 2030.

Pharmaceutical Contract Manufacturing Market Size to Hit USD 140 billion by 2030 Say, Roots Analysis

Retrieved on: 
Monday, January 15, 2024
Blister, Overalls, Route of administration, API, OneSource, Advent International, Investment, Acquisition, Medication, Drug development, Stelis, FDF, Baxter International, Organization, CDMO, CMOS, Clinical trial, Growth, Fine chemical

LONDON, Jan. 15, 2024 /PRNewswire/ -- The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reach USD 140 billion by 2030. It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period (2022-2030). 

Key Points: 
  • The global pharmaceutical contract manufacturing market faces challenges in the form of high initial investment costs for equipment and facilities.
  • Commercial segment will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 81% by 2030.
  • Based on the type of end users, the pharmaceutical contract manufacturing market is segmented into small, mid-sized, and large pharmaceutical companies.
  • Asia-Pacific will dominate the pharmaceutical contract manufacturing market during the forecast period and is anticipated to capture 37% of the market share by 2030.

Oligonucleotide Synthesis Market to Exceed 9.9 billion by 2035 Say, Roots Analysis

Retrieved on: 
Wednesday, January 10, 2024
Neurological disorder, Centre for Process Innovation, University of Manchester, Overalls, Oligonucleotide, Intrinsic termination, DNA, Nucleotide, API, DSM-IV codes, MicroRNA, University, Novartis, Small RNA, Genetic testing, COVID-19, EUR, Therapy, FDF, AstraZeneca, Fine chemical

LONDON, Jan. 10, 2024 /PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worth USD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035. It is estimated to grow at a compounded annual growth rate (CAGR) of 16.1% during the forecast period (2023-2035).

Key Points: 
  • The oligonucleotide synthesis market faces several challenges, including the complexity of synthesis procedures, purification difficulties, gaps in analytical expertise, cost intensiveness, and regulatory constraints.
  • The growth factors for the oligonucleotide synthesis market include the expanding applications of oligonucleotides in genetic testing, diagnostics, and therapeutics.
  • Recent Developments in Oligonucleotide Synthesis Market:
    Several recent developments have taken place in the field of oligonucleotide synthesis.
  • FDF operation will dominate the oligonucleotide synthesis market during the forecast period and is anticipated to capture 53% of the market share in 2023.

Oligonucleotide Synthesis Market to Exceed 9.9 billion by 2035 Say, Roots Analysis

Retrieved on: 
Wednesday, January 10, 2024
Neurological disorder, Centre for Process Innovation, University of Manchester, Overalls, Oligonucleotide, Intrinsic termination, DNA, Nucleotide, API, DSM-IV codes, MicroRNA, University, Novartis, Small RNA, Genetic testing, De novo synthesis, COVID-19, EUR, Therapy, FDF, AstraZeneca, Fine chemical

LONDON, Jan. 10, 2024 /PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worth USD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035. It is estimated to grow at a compounded annual growth rate (CAGR) of 16.1% during the forecast period (2023-2035).

Key Points: 
  • The oligonucleotide synthesis market faces several challenges, including the complexity of synthesis procedures, purification difficulties, gaps in analytical expertise, cost intensiveness, and regulatory constraints.
  • The growth factors for the oligonucleotide synthesis market include the expanding applications of oligonucleotides in genetic testing, diagnostics, and therapeutics.
  • Recent Developments in Oligonucleotide Synthesis Market:
    Several recent developments have taken place in the field of oligonucleotide synthesis.
  • FDF operation will dominate the oligonucleotide synthesis market during the forecast period and is anticipated to capture 53% of the market share in 2023.

Biz2X Launches Frontiers of Digital Finance Executive Event Series in the Middle East, Announces Riyadh Edition for Spring 2024

Retrieved on: 
Thursday, December 21, 2023
Finance, Professional Services, Technology, Fintech, Artificial Intelligence, Kingdom, AWS, Multimedia, King & Spalding, Qarar, Season, Mastercard, MENAT, New economy, FDF, Artificial intelligence, Piper, Growth, First Abu Dhabi Bank, The Business Council, DLA Piper, Amusement park

Biz2X has brought the internationally-acclaimed Frontiers of Digital Finance (FDF) event to Abu Dhabi.

Key Points: 
  • Biz2X has brought the internationally-acclaimed Frontiers of Digital Finance (FDF) event to Abu Dhabi.
  • Embracing the visionary theme, "Finance in 2030: How AI-Enabled Finance Will Propel Innovation, Entrepreneurship, and Shape the New Economy," the first Middle East event in the FDF conference series was a showcase of cutting-edge perspectives on the future of digital finance.
  • View the full release here: https://www.businesswire.com/news/home/20231221236454/en/
    Biz2X Launches Frontiers of Digital Finance Executive Event Series in the Middle East, Announces Riyadh Edition for Spring 2024 (Photo: Business Wire)
    Hosted with support from Biz2X partners DLA Piper , King & Spalding , ADGM , AWS , and the U.S. U.A.E.
  • Rohit Arora, CEO and Co-founder of Biz2X, said, “Our expansion into the Middle East is a strategic leap towards the future where finance and technology converge.

Xellia starts commercial production and distribution of premix bag products from its Cleveland facility

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Manufacturing, Other Manufacturing, Health, Pharmaceutical, Safety, Plant, Virginia Mason Medical Center, Investment, Patient, FDF, FDA, API, Health care, Medication, Pharmaceutical industry

The Xellia team has worked closely with the FDA to bring the whole Cleveland facility into operation, gaining approval for the commercial manufacturing of its first injectable drug products in March 2020 and now for its first premix bags, following regular inspections.

Key Points: 
  • The Xellia team has worked closely with the FDA to bring the whole Cleveland facility into operation, gaining approval for the commercial manufacturing of its first injectable drug products in March 2020 and now for its first premix bags, following regular inspections.
  • Xellia is one of the very few pharmaceutical manufacturers with the established technology to deliver aseptically filled premix bag capability.
  • “This FDA approval and the release of our first commercial batches from the Cleveland site are significant milestones for Xellia.
  • This is a great step forward in our strategy to enable the commercial production of our full product capabilities at Cleveland.